GlassScriptPhysician profile
Asa Alexander Mair
NPI 1306458062
$5,084.76
in general payments reported to CMS, 2019-2025
24 companies · $2,369 in 2025
The $2,369 reported for 2025 was more than what 95% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $89.11 · 2023: $550 · 2024: $2,077 · 2025: $2,369.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,835 · Education: $161.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,834.72 |
| Education | $160.93 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Supernus Pharmaceuticals, INC. | $728.76 | 2024-2025 | Qelbree |
| Otsuka America Pharmaceutical, INC. | $684.84 | 2023-2025 | Rexulti, Abilify Maintena, Abilify Asimtufii |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $633.13 | 2023-2025 | Caplyta |
| Teva Pharmaceuticals USA, INC. | $416.12 | 2024-2025 | Austedo Xr, Austedo Xr |
| Axsome Therapeutics, INC. | $375.76 | 2023-2025 | Auvelity |
| Alkermes, INC. | $348.36 | 2024-2025 | Aristada, Lybalvi |
| Abbvie INC. | $333.11 | 2023-2025 | |
| Vanda Pharmaceuticals INC. | $205.04 | 2024-2025 | Fanapt |
| Neurocrine Biosciences, INC. | $177.95 | 2024-2025 | Ingrezza |
| Corium, LLC | $172.18 | 2023-2024 | Azstarys, Azstarys |
| Janssen Pharmaceuticals, INC | $166.81 | 2023-2025 | Spravato |
| E.R. Squibb & Sons, L.L.C. | $162.15 | 2025 | Cobenfy |
| Neos Therapeutics, LP | $105.26 | 2024 | Adzenys Xr-Odt |
| Lundbeck LLC | $100.48 | 2023-2025 | Rexulti |
| Idorsia Pharmaceuticals US INC | $81.42 | 2024 | Quviviq |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alk-Abello, INC | $75.00 | 2021 | |
| Collegium Pharmaceutical, INC. | $66.83 | 2025 | Jornay Pm |
| Ironshore Pharmaceuticals INC. | $59.48 | 2024 | |
| Takeda Pharmaceuticals U.S.A., INC. | $59.12 | 2023-2025 | Trintellix |
| Tris Pharma INC | $46.66 | 2025 | Dyanavel Xr |
| Noven Therapeutics, LLC | $37.59 | 2023-2025 | Xelstrym, Secuado |
| Vertical Pharmaceuticals, LLC | $18.69 | 2025 | Relexxii |
| Almatica Pharma LLC | $15.91 | 2025 | Loreev Xr |
| Welch Allyn | $14.11 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Asa Mair listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.